Joseph Thibodeau, MD
Cardiovascular Disease · Omaha, NENPI 1316973381
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,858 of the $75,076 with a category attached, or 67.7%. 44 manufacturers reported payments, led by AstraZeneca at 43.0% of the total. Reporting peaked in 2019 at $25,453 and has fallen 86.7% since, to $3,383 in 2025. Among cardiovascular disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 709 payments — averaging $105.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$32K
- Novartis$23K
- Medtronic$8K
- Boston Scientific$1K
- Pfizer$1K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $7K from 38 others
Across 339 payments — averaging $519.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$71K
- Novo Nordisk AS$69K
- Boehringer Ingelheim International GmbH$36K
What the payments were for
- Speaking & faculty fees$50,85868%
- Travel & lodging$3,2284%
- Food & beverage$20,85928%
- Education$1300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$31,340
- ENTRESTO$21,444
- Performa$1,369
- Micra$1,169
- LINQ II$367
- AURORA EV-ICD MRI SURESCAN$339
- Evera$313
- ELIQUIS$268
- Azure$258
- NEXLETOL$244
- NEXLIZET$244
- Watchman$241
- AZURE XT DR MRI SURESCAN$224
- VYNDAQEL$215
- remede System$206
- SYNERGY ABLATION SYSTEM$184
- ATRICLIP LAA EXCLUSION SYSTEM$184
- SYMPLICITY G3$177
- Merlin Connectivity and Remote$175
- SAPIEN 3 Ultra RESILIA$173
How this compares
$75,076 in reported general payments places this provider in the 90th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 383 | $418,199 |
| FarxigaDapagliflozin Propanediol | 101 | $124,347 |
| EntrestoSacubitril/Valsartan | 101 | $121,145 |
| XareltoRivaroxaban | 82 | $83,663 |
| JardianceEmpagliflozin | 45 | $48,605 |
| Repatha SureclickEvolocumab | 52 | $37,258 |
| VascepaIcosapent Ethyl | 23 | $20,047 |
| Praluent PenAlirocumab | 25 | $14,329 |
| BrilintaTicagrelor | 12 | $8,837 |
| Icosapent Ethyl | 12 | $7,464 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $7,052 |
| Ranolazine ErRanolazine | 37 | $4,769 |
| Metoprolol Succinate | 363 | $3,758 |
| Atorvastatin Calcium | 448 | $3,328 |
| Ezetimibe | 138 | $2,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,226 | $418,199383 claims |
| AstraZenecaFarxiga, Brilinta | $32,253 | $133,185113 claims |
| NovartisEntresto | $23,424 | $121,145101 claims |
| Johnson & JohnsonXarelto | $231 | $83,66382 claims |
| Boehringer IngelheimJardiance | $869 | $48,60545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- John HenryOmaha$79K
- Qais RadaidehOmaha$50K
- Edward OlearyOmaha$36K
- Faris KhanOmaha$17K
- Michael PetersOmaha$13K
- Thomas PorterOmaha$11K
- Gregory PavlidesOmaha$10K
- Shiva PonamgiOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.